SBT6050, a novel therapeutic comprised of a potent TLR8 agonist conjugated to a HER2 directed monoclonal antibody, is delivered systemically with tumor localized activation of myeloid cells.
Solid tumors, including those resistant to T cell targeted immunotherapy such as PD-1 and CTLA-4 blockade, are replete with myeloid cells. Activation and reprogramming of myeloid cells drives an innate immune response resulting in direct tumor killing and can also nucleate a T cell response.
Successful activation of myeloid cells can lead to anti-tumor immunity, even in tumors that are resistant to immune checkpoint blockade, bringing substantial benefit to patients. TLR8 is the optimal target for activation and reprogramming of various myeloid cell types in the tumor microenvironment due to its restricted expression and function within such myeloid cells.